Luis Jodar

Pfizer, Inc. - Vaccines Medical Development & Scientific Affairs

SCHOLARLY PAPERS

4

DOWNLOADS
Rank 27,200

SSRN RANKINGS

Top 27,200

in Total Papers Downloads

2,859

SSRN CITATIONS

0

CROSSREF CITATIONS

0

Scholarly Papers (4)

1.

BNT162b2 (Pfizer–Biontech) mRNA COVID-19 Vaccine Against Omicron-Related Hospital and Emergency Department Admission in a Large US Health System: A Test-Negative Design

Number of pages: 25 Posted: 18 Jan 2022
Kaiser Permanente Southern California - Department of Research & Evaluation, Kaiser Permanente Southern California - Department of Research & Evaluation, Pfizer, Inc., Kaiser Permanente Southern California - Department of Research & Evaluation, Kaiser Permanente Southern California, Kaiser Permanente Southern California, Pfizer, Inc., Pfizer, Inc. - Vaccines Medical Development & Scientific Affairs and Pfizer, Inc.
Downloads 2,104 (11,263)

Abstract:

Loading...

omicron, effectiveness, waning, booster, third dose, BNT162b2, SARS-CoV-2, COVID-19, United States, test-negative, kaiser

2.

BNT162b2 Effectiveness and Durability Against BA.1 and BA.2 Hospital and Emergency Department Admissions in a Large US Health System: A Test-Negative Design

Number of pages: 25 Posted: 30 Jun 2022
Kaiser Permanente Southern California - Department of Research & Evaluation, Kaiser Permanente Southern California - Department of Research & Evaluation, Pfizer, Inc., Kaiser Permanente Southern California - Department of Research & Evaluation, Kaiser Permanente Southern California, Kaiser Permanente Southern California, Pfizer, Inc., Pfizer, Inc. - Vaccines Medical Development & Scientific Affairs and Pfizer, Inc.
Downloads 381 (118,405)

Abstract:

Loading...

BA.2, BA.1, omicron, effectiveness, BNT162b2, SARS-CoV-2, COVID-19, United States, test-negative, Kaiser Permanente, real-world

3.

Effectiveness of a Third Dose of BNT162b2 mRNA COVID-19 Vaccine in a Large US Health System: A Retrospective Cohort Study

Number of pages: 35 Posted: 21 Dec 2021
Kaiser Permanente Southern California - Department of Research & Evaluation, Kaiser Permanente Southern California - Department of Research & Evaluation, Pfizer, Inc., Kaiser Permanente Southern California - Department of Research & Evaluation, Kaiser Permanente - Kaiser Permanente Center for Integrated Health Care Research, Kaiser Permanente Southern California, Kaiser Permanente Southern California - Department of Research & Evaluation, Kaiser Permanente Southern California - Department of Research & Evaluation, Kaiser Permanente Southern California - Department of Research & Evaluation, Pfizer, Inc., Pfizer, Inc., Pfizer, Inc., Pfizer, Inc., Pfizer, Inc. - Vaccines Medical Development & Scientific Affairs and Pfizer, Inc.
Downloads 361 (125,893)

Abstract:

Loading...

effectiveness, waning, booster, third dose, BNT162b2, SARS-CoV-2, COVID-19, United States, cohort, delta

4.

Impact of SARS-CoV-2 Infective Exacerbation of Chronic Obstructive Pulmonary Disease (COPD) on Clinical Outcomes in a Prospective Cohort Study of Hospitalised Adults

Number of pages: 36 Posted: 21 Oct 2022
University of Bristol - Population Health Sciences, University of Bristol - Academic Respiratory Unit, University of Bristol - Academic Respiratory Unit, University of Bristol - Department of Mathematics, Pfizer, Inc. - Vaccines Medical Development & Scientific Affairs, Pfizer, Inc. - Vaccines Medical Development & Scientific Affairs, Pfizer, Inc. - Vaccines Medical Development & Scientific Affairs, Pfizer, Inc. - Vaccines Medical Development & Scientific Affairs, University Hospitals Bristol NHS Foundation Trust - Clinical Research and Imaging Centre, University of Bristol - Academic Respiratory Unit, University of Bristol - Bristol Vaccine Centre, University of Bristol - Academic Respiratory Unit, Pfizer, Inc. - Vaccines Medical Development & Scientific Affairs, University of Bristol - Bristol Vaccine Centre, University of Bristol - Department of Population Health Sciences, Pfizer, Inc. - Vaccines Medical Development & Scientific Affairs, Pfizer Inc. - Medical and Scientific Affairs, University of Bristol - Bristol Vaccine Centre, University of Bristol - Engineering Mathematics, University of Bristol - Academic Respiratory Unit and Independent
Downloads 13 (828,082)

Abstract:

Loading...

COVID-19, SARS-CoV-2, acute exacerbation of COPD, COPD, airways disease, respiratory infection